Dr. Jo-Fan Pan
PhD, University of Manchester; BSN, National Taiwan University. Leads Drugnews topic selection, business-analysis frameworks, long-form structure, and reader communication.
About Drugnews
We do not stop at headlines. We interpret whether clinical evidence, company strategy, licensing activity, manufacturing risk, and capital-market signals can change the business value of a company or a sector.
Editorial Standard
We prioritize clinical data, regulatory progress, company disclosures, licensing terms, and verifiable sources.
Mechanism, efficacy, safety, CMC, competition, payment structure, and market positioning are interpreted together.
We try to distinguish disclosed facts, reasonable inference, and unresolved uncertainty.
Website articles preserve titles, dates, canonical URLs, references, and citation guidance for long-term use.
Drugnews serves biotech investors, industry professionals, BD and IR teams, and readers learning how to interpret biotech companies.
Products, platforms, competitors, clinical milestones, cash runway, and market positioning organized into trackable company judgment.
Endpoints, safety, manufacturing, supply chain, and regulatory signals interpreted as commercial evidence.
Upfront payments, milestones, royalties, options, territory rights, and deal risk explained through buyer and seller incentives.
rNPV, SOTP, peak sales, peer comparisons, and capital-market sentiment used to explain why assets are repriced.
Drugnews may work with companies on feature articles, interviews, IR narratives, event recaps, and company-service content. Collaboration must be based on public information, company-approved disclosure, and professional research frameworks.
Collaboration content should not include undisclosed material information, insider information, or unauthorized details.
Our content work aims to improve understanding and communication quality. It does not promise share-price, volume, fundraising, or investor behavior outcomes.
Even in collaboration content, Drugnews keeps basic fact-checking, risk disclosure, and industry context.
Drugnews turns clinical data, company strategy, licensing activity, and capital-market signals into clear business judgment for biotech and pharmaceutical readers.
We cover company research, clinical and CMC risks, licensing and BD, valuation, and capital-market signals. The goal is not to summarize news, but to explain which evidence can change business value.
Team
Drugnews is built by Dr. Jo-Fan Pan and Dr. Chuan-Sheng Lin, combining clinical medicine, biotech R&D, business development, and capital-market perspectives. The editorial goal is to turn biotech information into research material readers can inspect, compare, and track.
PhD, University of Manchester; BSN, National Taiwan University. Leads Drugnews topic selection, business-analysis frameworks, long-form structure, and reader communication.
Biomedical dual-PhD background with more than 15 years across the biotech and pharmaceutical R&D value chain, helping review scientific evidence, technical barriers, and development risk.